<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Cohn AM</submitter><funding>Center for Tobacco Products</funding><funding>NIDA NIH HHS</funding><funding>NIAID NIH HHS</funding><funding>National Institute on Drug Abuse</funding><pagination>e067694</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9680144</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(11)</volume><pubmed_abstract>&lt;h4>Introduction&lt;/h4>The Food and Drug Administration (FDA) announced its intention to reduce the nicotine content in cigarettes as a strategy to promote cessation and reduce smoking-related harm. A low nicotine product standard will apply to all cigarettes on the market, including menthol cigarettes. In December 2021, the FDA approved a modified risk tobacco product application for menthol and non-menthol flavoured very low nicotine cigarettes (VLNC) from the 22nd Century Group. Notably, experimentation with menthol cigarettes is linked to smoking progression, as well as greater nicotine dependence relative to non-menthol cigarette use. If menthol VLNCs are perceived as more appealing than non-menthol VLNCs, this would indicate that some aspect of menthol may maintain smoking even in the </pubmed_abstract><journal>BMJ open</journal><pubmed_title>Impact of a reduced nicotine standard on young adult appeal for menthol and non-menthol cigarettes.</pubmed_title><pmcid>PMC9680144</pmcid><funding_grant_id>R01 AI050900</funding_grant_id><funding_grant_id>R01DA050990-01</funding_grant_id><funding_grant_id>R01 DA050990</funding_grant_id><funding_grant_id>R01DA050990-02S1</funding_grant_id><pubmed_authors>Donny E</pubmed_authors><pubmed_authors>Ehlke SJ</pubmed_authors><pubmed_authors>Smith M</pubmed_authors><pubmed_authors>Denlinger-Apte R</pubmed_authors><pubmed_authors>Wyatt R</pubmed_authors><pubmed_authors>Cohen-Davidyan T</pubmed_authors><pubmed_authors>Villanti AC</pubmed_authors><pubmed_authors>Dunn D</pubmed_authors><pubmed_authors>Cassidy R</pubmed_authors><pubmed_authors>Hatsukami D</pubmed_authors><pubmed_authors>Cohn AM</pubmed_authors><pubmed_authors>Niznik T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Impact of a reduced nicotine standard on young adult appeal for menthol and non-menthol cigarettes.</name><description>&lt;h4>Introduction&lt;/h4>The Food and Drug Administration (FDA) announced its intention to reduce the nicotine content in cigarettes as a strategy to promote cessation and reduce smoking-related harm. A low nicotine product standard will apply to all cigarettes on the market, including menthol cigarettes. In December 2021, the FDA approved a modified risk tobacco product application for menthol and non-menthol flavoured very low nicotine cigarettes (VLNC) from the 22nd Century Group. Notably, experimentation with menthol cigarettes is linked to smoking progression, as well as greater nicotine dependence relative to non-menthol cigarette use. If menthol VLNCs are perceived as more appealing than non-menthol VLNCs, this would indicate that some aspect of menthol may maintain smoking even in the </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2026-05-27T23:30:52.708Z</modification><creation>2025-04-03T23:17:09.42Z</creation></dates><accession>S-EPMC9680144</accession><cross_references><pubmed>36410805</pubmed><doi>10.1136/bmjopen-2022-067694</doi></cross_references></HashMap>